465
Participants
Start Date
August 31, 2002
Primary Completion Date
December 31, 2012
Study Completion Date
December 31, 2012
Rituximab
Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
Methotrexate
Participants will receive methotrexate 10-25 mg/week orally or parenterally.
Methylprednisolone
Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
Folic Acid
Participants will receive folic acid \>= 5 mg/week or equivalent.
Auckland
Melbourne
Maroochydore
Perth
Ghent
Mexico City
Great Neck
Smithtown
Plainview
Rochester
Santiago de Compostela
Genoa
Duncansville
Heinola
Milan
Winston-Salem
Greenville
Madrid
Madrid
Madrid
Udine
South Miami
Aventura
Fort Lauderdale
Boca Raton
Largo
Birmingham
San Cristóbal de La Laguna
Ratingen
Seville
Modena
Beachwood
Mayfield
México
Dayton
Indianapolis
Cologne
Glendale
Wausau
Minneapolis
Chicago
Chicago
St Louis
Monterrey
Little Rock
Tulsa
Tulsa
Dallas
Houston
Colorado Springs
Boise
Salt Lake City
Peoria
La Jolla
San Diego
Rancho Mirage
Long Beach
Regensburg
Würzburg
Portland
Seattle
Haifa
Haifa
Indianapolis
Boston
Lebanon
Voorhees Township
Curtiba
Campinas
São Paulo
Calgary
Vancouver
St. John's
London
Prague
Helsinki
Leipzig
Mexico City
Auckland
Bialystok
Lublin
Poznan
Warsaw
Wroclaw
Mérida
Gothenburg
Stockholm
Birmingham
Cambridge
Cannock
Leeds
Stoke-on-Trent
Collaborators (1)
Genentech, Inc.
INDUSTRY
Hoffmann-La Roche
INDUSTRY